Gilead Sciences Secures Exclusive Rights in $848 Million Deal with Compugen for Innovative Cancer Therapy

December 22, 2023

The UK first to approve bivalent COVID-19 vaccine

August 19, 2022

Series A funding by Orbital raises $270 million with the goal of developing next-gen RNA meds.

April 28, 2023

Must Read

Top 10 ESG Priorities for Life Sciences Companies

October 1, 2026

Continuous Manufacturing in Pharma Explained

October 1, 2026

Why Digital Manufacturing Is Becoming Essential

October 1, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Mirum’s Brelovitug Meets Main Goal in Phase 3 Chronic Hepatitis Delta Trial

Best-in-disease ambitions are fueled by Roche’s GLP-1/GIP medication’s success in a phase 2 diabetic trial

Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Misses Primary Endpoint

Bristol Myers Squibb Ends Development of Orum’s ORM-6151 After Phase 1 Review

Merck anticipates a significant win for the $3 billion eye disease opportunity

Novo and Lilly Trade New GLP-1 Data at Major Diabetes Meeting

Merck Signs Huge Deal With SciBrunch For KRAS G12D

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Top 10 ESG Priorities for Life Sciences Companies

Continuous Manufacturing in Pharma Explained

Why Digital Manufacturing Is Becoming Essential

Top 10 Technologies Modernizing Trial Monitoring

Insights

Addressing Unmet Need in Treatment-Resistant Cancers Through Purposeful R&D

Editor Picks

Gilead Sciences Secures Exclusive Rights in $848 Million Deal with Compugen for Innovative Cancer Therapy

The UK first to approve bivalent COVID-19 vaccine

Series A funding by Orbital raises $270 million with the goal of developing next-gen RNA meds.

Must Read

Top 10 ESG Priorities for Life Sciences Companies

Continuous Manufacturing in Pharma Explained

Why Digital Manufacturing Is Becoming Essential

Hot Topics

About Us

Follow Us